Drug Profile
BCX 1470
Latest Information Update: 04 Mar 2022
Price :
$50
*
At a glance
- Originator University of Alabama; University of Alabama at Birmingham
- Class Anti-inflammatories; Antihaemorrhagics
- Mechanism of Action Complement C1 inhibitors; Complement factor D inhibitors; Kallikrein inhibitors; Plasmin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Blood coagulation disorders; Reperfusion injury
Most Recent Events
- 30 Sep 1999 Discontinued-I for Coagulation disorders in USA (IV)
- 30 Sep 1999 Discontinued-I for Reperfusion injury in USA (IV)
- 27 Oct 1998 Phase-I clinical trials for Coagulation disorders in USA (IV)